(0.03%) 5 470.97 points
(0.08%) 39 143 points
(0.34%) 17 779 points
(-0.01%) $80.82
(-3.66%) $2.66
(-0.80%) $2 312.10
(0.18%) $28.92
(3.49%) $1 020.80
(0.24%) $0.935
(0.69%) $10.68
(0.42%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck...
Stats | |
---|---|
今日成交量 | 2.56M |
平均成交量 | 85 425 |
市值 | 1.05M |
EPS | $-1.230 ( Q1 | 2024-05-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0726 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0450 (21.94%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-01 | Luther Sanjeev | Buy | 1 685 218 | Stock Option (right to buy) |
2024-01-01 | Clarke Dorothy J | Buy | 168 521 | Stock Option (right to buy) |
2024-01-01 | Luther Sanjeev | Buy | 0 | |
2023-12-14 | Cherington Charles | Buy | 3 125 976 | Warrants (right to buy) |
2023-12-14 | Cherington Charles | Buy | 2 307 692 | Warrants (right to buy) |
INSIDER POWER |
---|
64.63 |
Last 79 transactions |
Buy: 23 565 099 | Sell: 3 570 325 |
音量 相关性
Eterna Therapeutics Inc. 相关性 - 货币/商品
Eterna Therapeutics Inc. 财务报表
Annual | 2023 |
营收: | $68 000.00 |
毛利润: | $-1.29M (-1 898.53 %) |
EPS: | $-4.08 |
FY | 2023 |
营收: | $68 000.00 |
毛利润: | $-1.29M (-1 898.53 %) |
EPS: | $-4.08 |
FY | 2022 |
营收: | $0 |
毛利润: | $-497 000 (0.00 %) |
EPS: | $-8.06 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-56.40 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Eterna Therapeutics Inc.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。